Price Momentum and Recent Performance
On 21 Jul 2026, Lupin’s share price closed at ₹2,478.30, up from the previous close of ₹2,442.10. The stock traded within a range of ₹2,450.05 to ₹2,493.00 during the day, inching closer to its 52-week high of ₹2,530.00. This recent price action reflects a positive short-term momentum, supported by a 1.48% day change, signalling renewed investor interest.
Over longer periods, Lupin’s returns have outpaced the benchmark Sensex significantly. Year-to-date, Lupin has delivered a robust 17.34% return compared to the Sensex’s negative 8.81%. Over one year, the stock surged 28.41%, while the Sensex declined by 4.95%. Even over three and five years, Lupin’s returns of 162.05% and 111.09% respectively dwarf the Sensex’s 15.00% and 48.87% gains, underscoring the company’s strong performance relative to the broader market.
Technical Indicator Analysis
The technical landscape for Lupin is complex, with several key indicators offering divergent signals. The Moving Average Convergence Divergence (MACD) remains bullish on both weekly and monthly charts, suggesting that the underlying momentum is still positive. This is complemented by bullish Bollinger Bands on the same timeframes, indicating that price volatility is contained within an upward trending channel.
Daily moving averages also support a bullish outlook, reinforcing the short-term strength in price action. However, the Relative Strength Index (RSI) presents a more cautious view. While the weekly RSI shows no clear signal, the monthly RSI is bearish, implying that the stock may be approaching overbought conditions or facing downward pressure in the medium term.
The Know Sure Thing (KST) oscillator adds to the mixed signals, registering mildly bearish readings on both weekly and monthly charts. This suggests some weakening in momentum that investors should monitor closely. Meanwhile, the Dow Theory analysis shows no clear trend on the weekly chart but remains bullish on the monthly timeframe, indicating that the longer-term trend is intact despite short-term fluctuations.
On-Balance Volume (OBV) data is similarly inconclusive, with no trend evident weekly and a mildly bearish stance monthly. This could reflect a lack of strong conviction among traders, with volume failing to confirm the recent price advances fully.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Technical Trend Shift and Market Implications
The overall technical trend for Lupin has shifted from bullish to mildly bullish, signalling a potential moderation in the pace of gains. This subtle change suggests that while the stock remains in an upward trajectory, investors should be alert to possible consolidation or minor pullbacks.
The mixed signals from momentum oscillators and volume indicators imply that the stock is at a technical crossroads. The bullish MACD and moving averages indicate that the uptrend is intact, but the bearish monthly RSI and KST readings warn of possible short-term corrections or sideways movement.
Given Lupin’s strong relative performance against the Sensex and its sector peers, the current technical setup may represent a healthy pause rather than a reversal. Investors with a medium to long-term horizon may find value in holding the stock, while short-term traders should watch for confirmation of trend continuation or signs of weakening momentum.
Valuation and Market Capitalisation Context
Lupin is classified as a mid-cap stock within the Pharmaceuticals & Biotechnology sector, carrying a Mojo Score of 77.0 and a current Mojo Grade of Buy, downgraded from Strong Buy on 13 Jul 2026. This adjustment reflects the recent technical moderation but still favours the stock’s prospects based on fundamental and technical assessments.
The company’s market capitalisation and sector positioning provide a solid foundation for growth, supported by ongoing pharmaceutical innovation and biotechnology advancements. Lupin’s ability to outperform the Sensex over multiple timeframes highlights its resilience and potential for sustained value creation.
Lupin Ltd. caught your attention? Explore our comprehensive research report with in-depth analysis of this mid-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth mid-cap analysis
- - Valuation assessment included
Investor Takeaways and Outlook
For investors analysing Lupin Ltd., the current technical signals suggest a cautious but optimistic stance. The bullish MACD and moving averages provide confidence in the stock’s upward momentum, while the bearish monthly RSI and KST indicators counsel prudence.
Given the stock’s strong outperformance relative to the Sensex and its sector, Lupin remains an attractive mid-cap option for those seeking exposure to Pharmaceuticals & Biotechnology. However, the recent downgrade from Strong Buy to Buy in the Mojo Grade signals that investors should monitor price action closely for signs of trend confirmation or reversal.
In summary, Lupin’s technical momentum has softened but remains constructive. The stock’s ability to maintain support above key moving averages and sustain bullish MACD readings will be critical for its near-term trajectory. Investors should balance the positive long-term fundamentals with the mixed technical signals to make informed decisions.
Comparative Performance Summary
To contextualise Lupin’s performance, the stock’s returns over various periods compared to the Sensex are as follows:
- 1 Week: Lupin -0.78%, Sensex +0.12%
- 1 Month: Lupin +5.37%, Sensex +1.18%
- Year-to-Date: Lupin +17.34%, Sensex -8.81%
- 1 Year: Lupin +28.41%, Sensex -4.95%
- 3 Years: Lupin +162.05%, Sensex +15.00%
- 5 Years: Lupin +111.09%, Sensex +48.87%
- 10 Years: Lupin +44.63%, Sensex +178.37%
These figures highlight Lupin’s exceptional medium-term growth, although the 10-year return lags the broader market, reflecting sector-specific dynamics and company evolution.
Conclusion
Lupin Ltd.’s recent technical parameter changes reveal a stock in transition, with momentum shifting from strong bullishness to a more tempered mildly bullish stance. The interplay of bullish MACD and moving averages against bearish RSI and KST indicators suggests a period of consolidation may be underway. Investors should weigh these signals alongside Lupin’s impressive relative returns and mid-cap status within the Pharmaceuticals & Biotechnology sector.
Maintaining vigilance on volume trends and momentum oscillators will be key to anticipating Lupin’s next directional move. For now, the stock remains a Buy-rated opportunity with potential for further gains, albeit with a need for careful monitoring of technical developments.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
